Role of α-II-spectrin breakdown products in the prediction of the severity and clinical outcome of acute traumatic brain injury

Chen,Shangyu; Shi,Qiankun; Zheng,Shuyun; Luo,Liangshen; Yuan,Shoutao; Wang,Xiang; Cheng,Zihao; Zhang,Wenhao

doi:10.3892/etm.2016.3153

Role of α-II-spectrin breakdown products in the prediction of the severity and clinical outcome of acute traumatic brain injury

Authors:
- Shangyu Chen
- Qiankun Shi
- Shuyun Zheng
- Liangshen Luo
- Shoutao Yuan
- Xiang Wang
- Zihao Cheng
- Wenhao Zhang
View Affiliations

Affiliations: Department of Critical Care Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China, Department of Neurosurgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
Published online on: March 11, 2016 https://doi.org/10.3892/etm.2016.3153
Pages: 2049-2053

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

αII-spectrin breakdown products are regarded as potential biomarkers for traumatic brain injury (TBI). The aim of the present study was to further evaluate these biomarkers by assessing their clinical utility in predicting the severity of injury and clinical outcome of patients with TBI. Eligible patients with acute TBI (n=17), defined by a Glasgow Coma Scale (GCS) score of ≤8, were enrolled. Ventricular cerebrospinal fluid (CSF) was sampled from each patient at 24, 72 and 120 h following TBI. An immunoblot assay was used to determine the concentrations of SBDPs in the CSF samples. The concentrations of SBDPs combined with the GCS score at 24 h after injury and the Glasgow Outcome Score (GOS) at 30 days after injury were compared and analyzed. The levels of SBDPs in CSF were markedly increased following acute TBI in comparison with those in the control group. In the early period after TBI, the levels of SBDPs were closely associated with GCS score. Comparisons of the SBDP levels with the severity of injury revealed significant differences between patients with the most severe brain injury and patients with severe brain injury in the first 24 h post‑injury (P<0.05). The levels and dynamic changes of SBDPs in CSF exhibited a close association with GOS at 30 days after injury. The levels of SBDPs differed significantly between patients grouped according to prognosis (P<0.05). These results suggest that in the early period after TBI, the levels and dynamic changes of SBDPs in CSF can be useful in the prediction of the severity of injury and clinical outcome of patients.

View Figures

View References

1	Perrin PB, Niemeier JP, Mougeot JL, Vannoy CH, Hirsch MA, Watts JA, Rossman W, Grafton LM, Guerrier TD, Pershad R, et al: Measures of injury severity and prediction of acute traumatic brain injury outcomes. J Head Trauma Rehabil. 30:136–142. 2015. View Article : Google Scholar : PubMed/NCBI
2	Brenner DJ and Hall EJ: Computed tomography-an increasing source of radiation exposure. N Engl J Med. 357:2277–2284. 2007. View Article : Google Scholar : PubMed/NCBI
3	Kmietowicz Z: Better safe than sorry? BMJ. 335:1182–1184. 2007. View Article : Google Scholar : PubMed/NCBI
4	Majno G and Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 146:3–15. 1995.PubMed/NCBI
5	Van Cruchten S and Van Den Broeck W: Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 31:214–223. 2002. View Article : Google Scholar : PubMed/NCBI
6	Wang KK: Calpain and caspase: Can you tell the difference? Trends Neurosci. 23:20–26. 2000. View Article : Google Scholar : PubMed/NCBI
7	Dressler J, Hanisch U, Kuhlisch E and Geiger KD: Neuronal and glial apoptosis in human traumatic brain injury. Int J Legal Med. 121:365–375. 2007. View Article : Google Scholar : PubMed/NCBI
8	Castillo MR and Babson JR: Ca(2+)-dependent mechanisms of cell injury in cultured cortical neurons. Neuroscience. 86:1133–1144. 1998. View Article : Google Scholar : PubMed/NCBI
9	Rathmell JC and Thompson CB: The central effectors of cell death in the immune system. Annu Rev Immunol. 17:781–828. 1999. View Article : Google Scholar : PubMed/NCBI
10	Raghupathi R: Cell death mechanisms following traumatic brain injury. Brain Pathol. 14:215–222. 2004. View Article : Google Scholar : PubMed/NCBI
11	Newcomb JK, Kampfl A, Posmantur RM, Zhao X, Pike BR, Liu SJ, Clifton GL and Hayes RL: Immunohistochemical study of calpain-mediated breakdown products to alpha-spectrin following controlled cortical impact injury in the rat. J Neurotrauma. 14:369–383. 1997. View Article : Google Scholar : PubMed/NCBI
12	Wang KK, Posmantur R, Nath R, McGinnis K, Whitton M, Talanian RV, Glantz SB and Morrow JS: Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem. 273:22490–22497. 1998. View Article : Google Scholar : PubMed/NCBI
13	Valiyaveettil M, Alamneh YA, Wang Y, Arun P, Oguntayo S, Wei Y, Long JB and Nambiar MP: Cytoskeletal protein α-II spectrin degradation in the brain of repeated blast exposed mice. Brain Res. 1549:32–41. 2014. View Article : Google Scholar : PubMed/NCBI
14	Pike BR, Flint J, Dave JR, Lu XC, Wang KK, Tortella FC and Hayes RL: Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 24:98–106. 2004. View Article : Google Scholar : PubMed/NCBI
15	Ringger NC, Tolentino PJ, McKinsey DM, Pike BR, Wang KK and Hayes RL: Effects of injury severity on regional and temporal mRNA expression levels of calpains and caspases after traumatic brain injury in rats. J Neurotrauma. 21:829–841. 2004. View Article : Google Scholar : PubMed/NCBI
16	Wilson JT, Pettigrew LE and Teasdale GM: Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: Guidelines for their use. J Neurotrauma. 15:573–585. 1998. View Article : Google Scholar : PubMed/NCBI
17	Narayan RK, Greenberg RP, Miller JD, Enas GG, Choi SC, Kishore PR, Selhorst JB, Lutz HA 3rd and Becker DP: Improved confidence of outcome prediction in severe head injury. A comparative analysis of the clinical examination, multimodality evoked potentials, CT scanning, and intracranial pressure. J Neurosurg. 54:751–762. 1981. View Article : Google Scholar : PubMed/NCBI
18	Choi SC, Clifton GL, Marmarou A and Miller ER: Misclassification and treatment effect on primary outcome measures in clinical trials of severe neurotrauma. J Neurotrauma. 19:17–22. 2002. View Article : Google Scholar : PubMed/NCBI
19	Reeves TM, Greer JE, Vanderveer AS and Phillips LL: Proteolysis of submembrane cytoskeletal proteins ankyrin-G and αII-spectrin following diffuse brain injury: A role in white matter vulnerability at nodes of ranvier. Brain Pathol. 20:1055–1068. 2010. View Article : Google Scholar : PubMed/NCBI
20	Schoch KM, von Reyn CR, Bian J, Telling GC, Meaney DF and Saatman KE: Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. J Neurochem. 125:909–920. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL and Wang KK: Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis. 14:1289–1298. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pike BR, Flint J, Dutta S, Johnson E, Wang KK and Hayes RL: Accumulation of non-erythroid alpha II-spectrin and calpain- cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem. 78:1297–1306. 2001. View Article : Google Scholar : PubMed/NCBI
23	Cardali S and Maugeri R: Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci. 50:25–31. 2006.PubMed/NCBI
24	Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, Demery JA, Liu MC, Aikman JM, Akle V, et al: Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 24:354–366. 2007. View Article : Google Scholar : PubMed/NCBI
25	Farkas O, Polgár B, Szekeres-Barthó J, Dóczi T, Povlishock JT and Büki A: Spectrin breakdown products in the cerebrospinal fluid in severe head injury-preliminary observations. Acta Neurochir (Wien). 147:855–861. 2005. View Article : Google Scholar : PubMed/NCBI
26	Schober ME, Requena DF, Davis LJ, Metzger RR, Bennett KS, Morita D, Niedzwecki C, Yang Z and Wang KK: Alpha II Spectrin breakdown products in immature Sprague Dawley rat hippocampus and cortex after traumatic brain injury. Brain Res. 1574:105–112. 2014. View Article : Google Scholar : PubMed/NCBI
27	Brophy GM, Pineda JA, Papa L, Lewis SB, Valadka AB, Hannay HJ, Heaton SC, Demery JA, Liu MC, Tepas JJ III, et al: alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 26:471–479. 2009. View Article : Google Scholar : PubMed/NCBI
28	Pike BR, Flint J, Dutta S, Johnson E, Wang KK and Hayes RL: Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem. 78:1297–1306. 2001. View Article : Google Scholar : PubMed/NCBI